The Future of Erectile Dysfunction Treatment: What Will Replace Viagra and Cialis? Introduction Since their introduction in the late 1990s, phosphodiesterase type 5 (PDE5) inhibitors, most notably Viagra (sildenafil) and Cialis (tadalafil), have fundamentally reshaped the treatment of erectile dysfunction. For many men, these drugs remain effective, well tolerated, and convenient. Yet their limitations are…

Abuse, Diversion, and Mortality: How Gabapentinoids Entered the Illicit Drug Market Introduction Gabapentin was never expected to end up here, in toxicology reports, overdose surveillance dashboards, and European drug mortality registries. When it was introduced in the 1990s as an anticonvulsant, and later repurposed for neuropathic pain, gabapentin carried the comforting aura of a medication…

Sildenafil in 2025: A Fully Standardized Global Manufacturing Commodity Sildenafil Manufacturing in 2025: A Fully Standardized Generic Project In 2025, sildenafil has reached a stage that few once imagined for a drug that began its life as one of the most profitable pharmaceuticals in history: it is now a standardized industrial product, produced in high…

Counterfeit, “Natural,” and Gray-Market Sildenafil in 2025: A Major Challenge for the Legitimate Generic Industry France’s “Viagra honey” crisis and the rise of adulterated natural aphrodisiacs One of the most striking developments of 2025 in the European ED-drug landscape is the explosion of “Viagra honey”, also known as “love honey,” “miel aphrodisiaque,” or “miel bleu.”…

Global Prescription Status of Sildenafil in 2025: Over-the-Counter Is Rare Exception, Prescription the Rule Most of the world still requires a prescription for sildenafil Most of the world still requires a prescription for sildenafil As of 2025, in nearly all major markets, including the European Union, the United States, Canada, and many others, Sildenafil (generic…

A New "Super-Viagra" (Simenafil) and Its Consequences for the Generic Sildenafil Market Simenafil as a New PDE5 Inhibitor: What the Phase III Data Show Simenafil's arrival in 2025 marks the first genuinely new PDE5 inhibitor to reach late-stage clinical development in over a decade, and its emergence is being watched closely by both clinicians and…

Sildenafil in 2025: A Fully Mature, Commodity-Level Generic Market Market size and why 2025 marks full maturity The global sildenafil market in 2025 is estimated at approximately $3.3–3.9 billion, according to industry analyses from Coherent Market Insights. The exact figure varies slightly depending on methodology, but all reports converge on the same qualitative finding: growth…

Sildenafil Prices in 2025: Generics Keep Getting Cheaper Price trajectory after patent expiration Price tracking data indicate that once exclusivity expired, generic sildenafil began decreasing in price at a rate of approximately 3–5% per year, driven not by clinical developments, but by pure market mechanics. This downward trend is a product of competitive saturation: once…